JAK / Stat

9 Item(s)

per page

Set Descending Direction
  1. CO-1686 (Rociletinib, AVL-301)

    Catalog No. A13028
    Quick View
    EGFR inhibitor
    CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). Learn More
  2. Afatinib dimaleate

    Catalog No. A14985
    Quick View
    EGFR inhibitor
    Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. Learn More
  3. CNX-2006

    Catalog No. A13755
    Quick View
    EGFR inhibitor
    CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer. Learn More
  4. EGF816 (Nazartinib)

    Catalog No. A14416
    Quick View
    EGFR T790M inhibitor
    EGF816 is a novel covalent inhibitor of mutant-selective EGFR; overcomes T790M-mediated resistance in NSCLC. Learn More
  5. Icotinib Hydrochloride

    Catalog No. A13718
    Quick View
    EGFR inhibitor
    Icotinib hydrochloride is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). Learn More
  6. AZ5104

    Catalog No. A15516
    Quick View
    EGFR inhibitor
    AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1. Learn More
  7. Icotinib

    Catalog No. A13825
    Quick View
    EGFR inhibitor
    Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). Learn More
  8. AZD-9291 (Osimertinib)

    Catalog No. A13681
    Quick View
    EGFR inhibitor
    AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. Learn More
  9. ASP8273 (Naquotinib)

    Catalog No. A14408
    Quick View
    irreversible EGFR inhibitor
    ASP8273 is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Learn More

9 Item(s)

per page

Set Descending Direction
Rewards